Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain

被引：0
|
作者：
Eliazar Sabater
Armando López-Guillermo
Antonio Rueda
Antonio Salar
Itziar Oyagüez
Juan Manuel Collar
机构：
[1] Pharmacoeconomics and Outcomes Research Iberia,Haematology Department
[2] Hospital Clinic,Oncology Department
[3] Hospital Costa del Sol,Haematology Department
[4] Hospital del Mar,Medical Department
[5] Mundipharma Pharmaceuticals,undefined
来源：
Applied Health Economics and Health Policy | 2016年 / 14卷
关键词：
Follicular Lymphoma; Bendamustine; Bayesian Information Criterion; Progression State; Spanish National Health System;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：465 / 477
页数：12
相关论文
共 50 条
  • [21] High Risk of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated With First-line Bendamustine Rituximab and Rituximab Maintenance
    Rangel-Patino, Juan
    Kridel, Robert
    Kuruvilla, John
    Prica, Anca
    Kukreti, Vishal
    Bhella, Sita
    Delabie, Jan
    Vijenthira, Abi
    Crump, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S503 - S503
  • [22] A randomized trial of fludarabine and mitoxantrone plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma.
    Zinzani, PL
    BLOOD, 2001, 98 (11) : 842A - 842A
  • [23] COST-EFFECTIVENESS OF RITUXIMAB IN FOLLICULAR LYMPHOMA FIRST LINE MAINTENANCE TREATMENT FROM PUBLIC PAYER PERSPECTIVE IN POLAND
    Gadaj, A.
    Kalinowska, A.
    Hawrylecka, D.
    Holojda, J.
    Krawcewicz, A.
    Spychalowicz, W.
    Russel-Szymczyk, M.
    Szkultecka-Debek, M.
    VALUE IN HEALTH, 2011, 14 (07) : A449 - A450
  • [24] COST-EFFECTIVENESS OF BENDAMUSTINE-RITUXIMAB IN FIRST-LINE INDOLENT NHL: A PATIENT-LEVEL SIMULATION
    Dewilde, S.
    Woods, B.
    Castaigne, J. G.
    Parker, C.
    Dunlop, W.
    VALUE IN HEALTH, 2013, 16 (07) : A415 - A415
  • [25] Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway
    Fredrik Salvesen Haukaas
    Audun Ohna
    Tania Krivasi
    Applied Health Economics and Health Policy, 2018, 16 : 569 - 577
  • [26] Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway
    Haukaas, Fredrik Salvesen
    Ohna, Audun
    Krivasi, Tania
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2018, 16 (04) : 569 - 577
  • [27] First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis
    Pouyiourou, M.
    Meyer, A.
    Stroux, A.
    Viardot, A.
    La Rosee, P.
    Maschmeyer, G.
    Kaempfe, D.
    Kahl, C.
    Vucinic, V.
    Monecke, A.
    Hirt, C.
    Weber, T.
    Meissner, J.
    Witzens-Harig, M.
    Boettcher, S.
    Schmalenberg, H.
    Marks, R.
    Prange-Krex, G.
    Kroschinsky, F.
    Hauf, E.
    Keller, U.
    Koch, K.
    Klapper, W.
    Herold, M.
    Scholz, Christian W.
    ANNALS OF HEMATOLOGY, 2020, 99 (12) : 2821 - 2829
  • [28] First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A—results of a retrospective analysis
    M. Pouyiourou
    A. Meyer
    A. Stroux
    A. Viardot
    P. La Rosée
    G. Maschmeyer
    D. Kämpfe
    C. Kahl
    V. Vucinic
    A. Monecke
    C. Hirt
    T. Weber
    J. Meissner
    M. Witzens-Harig
    S. Böttcher
    H. Schmalenberg
    R. Marks
    G. Prange-Krex
    F. Kroschinsky
    E. Hauf
    U. Keller
    K. Koch
    W. Klapper
    M. Herold
    Christian W. Scholz
    Annals of Hematology, 2020, 99 : 2821 - 2829
  • [29] CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
    Marcus, R
    Imrie, K
    Belch, A
    Cunningham, D
    Flores, E
    Catalano, J
    Solal-Celigny, P
    Offner, F
    Walewski, J
    Raposo, J
    Jack, A
    Smith, P
    BLOOD, 2005, 105 (04) : 1417 - 1423
  • [30] ECONOMIC EVALUATION OF BENDAMUSTINE PLUS RITUXIMAB IN THE FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
    Lachaine, J.
    Kouroukis, C. T.
    VALUE IN HEALTH, 2016, 19 (03) : A248 - A248
12345